17 results about "Secretory protein" patented technology

An engineered cell and its application are provided. The engineered cell has nucleic acid encoded by a secreted protein specifically integrated at a B2M locus. This provides MSCs cells that can achieve long-term stable expression of secreted proteins, thereby ensuring the sustained therapeutic effect of MSCs cells and reducing the cost of medication for patients.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The application discloses a tomato Soly04g076730 Gene or its encoded protein is applied to resisting plant geminivirus. Soly04g076730 The gene is transiently expressed or stably genetically transformed in a plant leaf. When a virus invades the plant, the plant immune response is rapidly induced, and the disease resistance of the plant is improved. The Soly04g076730 protein is a secretory protein. The plant immune ability can be improved by expressing or externally applying the protein in the plant, and the virus transmission and replication can be effectively inhibited.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

The present disclosure provides a protein-vesicle conjugate, comprising one or more secretory proteins or a fragment thereof expressed on or conjugated to a surface of a vesicle and optionally an agent, and a method for delivery of an agent with the protein-vesicle conjugate across a biological barrier to a cell and tissue containing the cell.

This invention relates to compounds, compositions and methods for preventing or treating malaria by modulating immune responses through Killer-specific Secretory Protein 37 (Ksp37). The invention provides for the administration of Ksp37, or stimulation of endogenous Ksp37 production using polar compounds such as DMF or DMSO, to increase Ksp37 levels in a subject to therapeutically effective concentrations. Elevated Ksp37 enhances cytotoxic CD8+ T-cell and NK-cell activity, supports cytokine balance, and improves immune clearance of Plasmodium parasites during both liver and blood stages. These approaches promote targeted immune activation, reduce parasite survival, and improve host protection against malaria infection.

The disclosure provides use of a protein-vesicle conjugate in the preparation of a medicament for delivering an agent across a biological barrier to a cell and / or a tissue containing the cell, the protein-vesicle conjugate comprising one or more secreted proteins or fragments thereof expressed on or bound to the surface of a vesicle and optionally an agent.

This invention discloses secretory proteins of pluripotent stem cells (EPSCs), combinations thereof, and their application in the preparation of agents for delaying the aging of human mesenchymal stem cells (MSCs). The application of S100A9 protein, S100A8 protein, GAPDH protein, or any combination thereof in the preparation of agents for delaying the aging of human mesenchymal stem cells (MSCs); the amino acid sequence of the S100A9 protein is shown in SEQ ID NO.1, the amino acid sequence of the S100A8 protein is shown in SEQ ID NO.3, and the amino acid sequence of the GAPDH protein is shown in SEQ ID NO.5. This invention studies the secretory proteins of EPSCs to discover and explore anti-aging factors, identifies secretory proteins with the effect of delaying MSC aging, provides a potential solution for reducing in vitro expansion and aging of MSCs and improving their therapeutic effects, and also provides a new perspective for anti-MSC aging research.

The present disclosure provides a protein-vesicle conjugate, a pharmaceutical composition comprising the protein-vesicle conjugate, and use of the protein-vesicle conjugate in the preparation of a medicament for delivering a pharmaceutical agent to autophagic and / or apoptotic cells and tissues containing the cells. The protein-vesicle conjugate comprises one or more secreted proteins or fragments thereof expressed on or bound to the surface of a vesicle and optionally a pharmaceutical agent.

The present invention relates to a recombinant activation-associated secreted protein (ASP) or fragment thereof, said ASP or fragment comprising an N-glycan comprising a core α1,3-fucose and / or a core α1,6-fucose (Fuc). The invention further relates to a pharmaceutical composition comprising such a recombinant ASP or fragment thereof. Additionally, the invention relates to the recombinant ASP or fragment thereof for use as a human or veterinary medicine, in particular as a vaccine, more in particular for use against parasitic nematode infections.

This invention discloses a targeted protein degradation system based on TEEP protein-signal peptide recognition and its application, belonging to the field of biotechnology. The system comprises a TEEP protein or a functional variant thereof capable of specifically recognizing a signal peptide, and a signal peptide tag that can be fused to the N-terminus of a target protein. By fusing the tag with the target protein and expressing it, specific degradation of the target protein can be achieved in the presence of the TEEP protein. This system requires no exogenous inducer, has a short tag with minimal interference, and is particularly suitable for the targeted degradation of secretory and membrane proteins, providing a novel and universal tool for protein function research, drug target validation, and high-throughput screening.

This invention relates to the field of single-cell functional analysis and microfluidic chip technology, and discloses a kit and method for in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell. The kit includes: a microcavity array chip; a secreted protein capture antibody barcode chip and an intracellular protein capture antibody barcode chip; a plastic clamp; a bioaffinity modification reagent; secreted protein standards, intracellular protein standards, secreted protein detection antibody stock solution, and intracellular protein detection antibody stock solution; a fluorescent conjugate, antibody buffer, antibody blocking solution, cell lysis buffer, and cell washing buffer. The method of this invention, through a sequential detection process of first capturing and incubating secreted proteins, followed by in-situ lysis to capture intracellular proteins, achieves high-throughput, high-sensitivity, and high-specificity in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell without cell transfer or loss of spatial location information. It can establish a correlation analysis of "intracellular signaling pathway activation - external functional output" in single cells, providing a powerful tool for disease mechanism research, drug screening, and immunotherapy evaluation.

The application discloses a feed formula containing amino acids and a configuration method, which comprises culture medium components and microbial strains, wherein the culture medium components are composed of protein powder, yellow sugar powder, amino acids and pure water, and the microbial strains are composed of Bacillus subtilis, Bacillus licheniformis, Pediococcus pentosaceus, lysozyme, protease, Lactobacillus plantarum, Saccharomyces cerevisiae, Bacillus coagulans and Lactobacillus acidophilus. Through the synergistic effect of multiple strains and enzymes, the protein conversion efficiency and the amino acid absorption effect are significantly improved; the Bacillus subtilis and the Bacillus licheniformis inoculated in the aerobic stage can secrete protease and amylase, and preliminarily decompose macromolecular proteins in the protein powder; the Lactobacillus plantarum supplemented in the anaerobic stage reduces the pH of the feed to 4.2-4.8, provides an optimal catalytic environment for the protease, and further decomposes small molecular peptides into free amino acids, so that the protein decomposition rate is improved.

The application discloses a method for semi-quantitative analysis of expression level of secreted protein of human joint cartilage cells by using immunoblotting technology. The method comprises the following steps: 1) preparing a secreted protein culture solution; 2) collecting a sample of the secreted protein culture solution; 3) performing dialysis desalting treatment on the sample; 4) concentrating the secreted protein culture solution to prepare a powder; 5) re-dissolving the secreted protein culture solution powder and quantifying the protein; 6) separating the protein components in the re-dissolved culture solution; and 7) detecting the expression level of the secreted protein in the re-dissolved culture solution sample by using immunoblotting method. The low-temperature dialysis and vacuum concentration technology can significantly improve the concentration of the secreted protein in the human joint cartilage tissue culture solution sample under the condition of maintaining the integrity of the protein structure, and is suitable for detecting the chemical fluorescence signal of the secreted protein in the sample by using the immunoblotting technology. The application provides an important cell reaction detection tool for studying the pathogenesis of bone and joint diseases caused by degenerative changes of cartilage tissue and researching and developing biological small-molecule drugs for treating the diseases.

Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.

Provided are chimeric molecules, compositions, and applications thereof that specifically bind to natriuretic peptide receptor C (NPR-C). The disclosed chimera comprises an NPR-C binding domain and a target-binding domain. Through NPR-C-mediated endocytosis, the chimera enables the intracellular degradation of the target by lysosomal enzymes. The chimeric molecules can rapidly, conveniently, and precisely degrade target proteins. Their modular design permits broad applicability to proteins such as secreted proteins and membrane-associated proteins. These chimeric molecules exhibit high bioavailability and low immunogenicity, thus being broadly applicable for the treatment of diseases including cancer, neurodegenerative diseases, psychiatric disease, central nervous system diseases, inflammatory diseases, autoimmune diseases, metabolic syndrome, tissue fibrotic disease, cardiovascular diseases, respiratory diseases, digestive diseases, renal diseases, hematologic diseases, infectious diseases, rare diseases and aging-related disease.

The application discloses a type IV secretory effector protein recognition method and system based on multi-modal information, and belongs to the technical field of bioinformatics and secretory protein recognition. The amino acid residue features of the protein are extracted by using a protein language model, and a spatial adjacency graph of the protein is constructed by using a three-dimensional structure predicted by a protein structure prediction model; then, sequence features and structure features of the protein are extracted by a deep sequence module and a hierarchical graph module respectively; meanwhile, a contrast learning module is introduced to realize cross-modal alignment of the same protein in a latent space; the sequence features and the structure features are bidirectionally interacted by using a cross attention module to obtain joint features, and finally, a classification result is output after a nonlinear transformation of a gate linear unit, and is used for prediction of the type IV secretory effector protein. The application realizes efficient cooperation of sequence and structure double modal information, and significantly improves the accuracy of type IV secretory effector protein recognition.